Recommended

Novo Nordisk bids $6.5bn for Metsera Therapeutics
MHRA to streamline UK rare disease drug regulatory pathway
Lilly invests €2.6bn in Netherlands manufacturing facility
MHRA recruits first Chief Medical and Scientific Officer
Galapagos to exit cell therapy business
Chiesi expands French metered dose inhaler facility
CPHI Milan to add AI zone for 2026
Hovione invests $100m in US spray drying manufacturing
news

J&J agrees to manufacture 100 million doses of COVID-19 vaccine for US

1
SHARES

J&J will supply the US with 100 million doses of the company’s COVID-19 vaccine candidate following an agreement with the country’s government.

COVID-19 vaccine

Johnson & Johnson (J&J) has announced that Janssen has entered into an agreement with the US government for the manufacturing and delivery of 100 million doses of the company’s COVID-19 vaccine.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The investigational vaccine, Ad26.COV2.S, will be used in the US following the approval or emergency use authorisation (EUA) from the US Food and Drug Administration (FDA).

The US Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, in collaboration with the US Department of Defense, is committing over $1 billion for this agreement. According to J&J, the vaccine will be provided at a global not-for-profit basis for emergency pandemic use. The government may also purchase an additional 200 million doses of Ad26.COV2.S under a subsequent agreement.

“J&J’s global team of experts has worked tirelessly alongside BARDA and scientific partners to pursue a SARS-CoV-2 vaccine that can help to stop the spread of COVID-19. We greatly appreciate the US government’s confidence in, and support for, our R&D platform and efforts and the scalability of our vaccine technology. We are scaling up production in the US and worldwide to deliver a SARS-CoV-2 vaccine for emergency use,” said Dr Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer at J&J.

Novavax presents positive data from Phase I COVID-19 vaccine trial…

The Phase I/IIa first-in-human clinical trial of Ad26.COV2.S is currently underway in healthy volunteers in the US and Belgium.

The company is evaluating both one- and two-dose regimens in its clinical programme and working towards global access of the vaccine following either approval or authorisation by regulators. J&J says it aims to meet its goal to supply goal of more than one billion doses globally throughout the course of 2021, provided the vaccine is safe and effective.

Share via
Share via